Nurix Therapeutics, Inc. Reports 2025 Annual Results: A Year of Progress Amidst Challenges

Founded with the mission to enhance treatment options for patients suffering from cancer and inflammatory diseases, Nurix has leveraged its proprietary DEL-AI platform to accelerate the discovery and development of novel therapies. The company’s pipeline includes targeted protein degraders, such as bexobrutideg (NX-5948) and zelebrudomide (NX-2127), which are currently undergoing various stages of clinical trials aimed at treating challenging malignancies.

In 2025, Nurix initiated a Phase 2 study of bexobrutideg, a promising BTK degrader for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). This trial commenced in October and is viewed as a pivotal step toward securing Accelerated Approval from the FDA, which granted Fast Track designation for bexobrutideg in January 2024.

Zelebrudomide is currently in a Phase 1a/1b study for relapsed or refractory B-cell malignancies. After a temporary pause due to a manufacturing hold in 2023, enrollment resumed in August 2024, demonstrating Nurix's commitment to advancing its clinical programs.

Despite the promising developments, Nurix reported a net loss of $264.4 million for the fiscal year ending November 30, 2025, an increase from a net loss of $193.6 million in 2024. The company's revenue reached $83.98 million, driven by collaboration and license revenues, yet still fell short of covering operational costs.

The company's revenue for 2025 consisted of $53.98 million in collaboration revenue, slightly down from $54.54 million in 2024, with new license revenue of $30 million reflecting successful licensing agreements, particularly with Sanofi.

Research and development expenses surged to $316.9 million, reflecting increased trial costs and personnel expenses. General and administrative expenses also rose to $52.74 million. In response to the heightened expenditure, Nurix raised approximately $250 million through a registered offering of common stock in October 2025.

Despite the operating losses, Nurix's liquidity position remains strong, with $592.9 million in cash and marketable securities, providing a runway for at least the next 12 months.

As of November 30, 2025, Nurix reported total assets of $688.1 million, up from $669.3 million in 2024. Liabilities increased to $149.3 million, while equity rose to $538.7 million, reflecting a solid capital structure supported by substantial equity financing.

Nurix continues to enhance its position in the biopharmaceutical landscape through strategic collaborations. Notable partnerships include:

The macroeconomic environment remains challenging, with financial market volatility and inflationary pressures posing risks. Nurix is proactively monitoring these conditions, focusing on maintaining a robust operational framework.

Moving forward, Nurix is poised to expand its clinical portfolio while advancing collaborations that promise both non-dilutive funding and potential milestone payments. The company's commitment to innovation in targeted protein degradation positions it favorably in the competitive biopharmaceutical landscape.

As Nurix Therapeutics closes the chapter on 2025, the company showcases resilience amid financial challenges and a robust pipeline poised for potential breakthroughs. With strategic collaborations and a focus on delivering innovative therapies, Nurix is set to navigate the complexities of the biopharmaceutical industry while prioritizing patient outcomes.